The inhibition of NF-κB activation in AD mouse models has been demonstrated to slow the AD pathology and improve neuronal survival and cognition, implicating that the use of NF-κB antagonists could provide therapeutic benefit (76, 77). Here, NFKB1 is linked to Alzheimer disease.